A study on associations between antiprothrombin antibodies, antiplasminogen antibodies and thrombosis

Journal of Thrombosis and Haemostasis

Volumn 1, Issue 4, 2003, Pages 735-739

  Simmelink, M J A ^a,b,c   de Root, P G ^a,c   Derksen, R H W M ^b  

^a Department of Haematology   (Netherlands)

^b University Medical Center   (Netherlands)

^c UTRECHT UNIVERSITY   (Netherlands)

Author keywords

Antiplasminogen antibodies; Antiprothrombin antibodies; Lupus anticoagulant; Thrombosis

Indexed keywords

AUTOANTIBODY; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; LUPUS ANTICOAGULANT; PLASMINOGEN; PROTHROMBIN;

ARTICLE; BLOOD; CASE CONTROL STUDY; HUMAN; IMMUNOLOGY; RISK FACTOR; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOSIS;

AUTOANTIBODIES; CASE-CONTROL STUDIES; HUMANS; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; LUPUS COAGULATION INHIBITOR; LUPUS ERYTHEMATOSUS, SYSTEMIC; PLASMINOGEN; PROTHROMBIN; RISK FACTORS; THROMBOSIS;

EID: 0142259265     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1046/j.1538-7836.2003.00137.x     Document Type: Article

References (18)

1. Wilson WA, Gharavi AE, Koike T, Lockshin MD, Branch DW, Piette JC, Brey R, Derksen R, Harris EN, Hughes GR, Triplett, DA, Khamashta MA. International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop. Arthritis Rheum 1999; 42: 1309-11.
2. Bevers EM, Galli M, Barbui T, Comfurius P, Zwaal RFA. Lupus anticoagulant IgG's (LA) are not directed to phospholipids only, but to a complex of lipid-bound human prothrombin. Thromb Haemost 1991; 66: 629-32.
3. Oosting JD, Derksen RHWM, Entjes HTI, Bouma BN, De Groot PhG. Lupus anticoagulant activity is frequently dependent on the presence of β2-glycoprotein I. Thromb Haemost 1992; 67: 499-502.
4. Roubey RAS, Pratt CW, Buyon JP, Winfield JB. Lupus anticoagulant activity of autoimmune antiphospholipid antibodies is dependent upon beta 2-glycoprotein I. J Clin Invest 1992; 90: 1100-4.
5. 2-glycoprotein I in the expression of lupus anticoagulant activity. Blood 1994; 83: 2878-92.
6. Galli M, Comfurius P, Maassen C, Hemker HC, de Baets MH, van Breda-Vriesman PJ, Barbui T, Zwaal RF, Bevers EM. Anticardiolipin antibodies (ACA) are directed not to cardiolipin but to a plasma protein cofactor. Lancet 1990; 335: 1544-7.
7. 2-glycoprotein I (apolipoprotein H). Proc Natl Acad Sci USA 1990; 87: 4120-4.
8. Horbach DA, Van Oort E, Donders RCJM, Derksen RHWM, De Groot PG. Lupus anticoagulant is the strongest risk factor for both venous and arterial thrombosis in patients with systemic lupus erythematosus -comparison between different assays for the detection of antiphospholipid antibodies. Thromb Haemost 1996; 76: 916-24.
9. Vaarala O, Puurunen M, Manttari M, Manninen V, Aho K, Palosuo T. Antibodies to prothrombin imply a risk of myocardial infarction in middle-aged men. Thromb Haemost 1996; 75: 456-9.
10. Puurunen M, Vaarala O, Julkunen H, Aho K, Palosuo T. Antibodies to phospholipid-binding plasma proteins and occurrence of thrombosis in patients with systemic lupus erythematosus. Clin Immunol Immuno-pathol 1996; 80: 16-22.
11. 2-glycoprotein I and anti prothrombin antibodies to thrombosis and pregnancy loss in patients with antiphospholipid antibodies. Thromb Haemost 1997; 78: 1008-14.
12. Palosuo T, Virtamo J, Haukka J, Taylor PR, Aho K, Puurunen M, Vaarala O. High antibody levels to prothrombin imply a risk of deep venous thrombosis and pulmonary embolism in middle-aged men - a nested case-control study. Thromb Haemost 1997; 78: 1178-82.
13. Puurunen M, Manninen V, Palosuo T, Vaarala O. Antibodies to prothrombin crossreact with plasminogen in patients developing myocardial infarction. Br J Haematol 1998; 100: 374-9.
14. Puurunen M, Palosuo T, Lassila R, Anttila M, Vaarala O. Immunologic and hematologic properties of antibodies to prothrombin and plasminogen in a mouse model. Lupus 2001; 10: 108-15.
15. Castellino FJ, Beals JM. The genetic relationships between the kringle domains of human plasminogen, prothrombin, tissue plasminogen aktivator, urokinase and coagulation factor XII. J Mol Evaluation 1987; 26: 358-69.
16. Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, Schaller JG, Talal N, Winchester RJ. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982; 25: 1271-7.
17. Koedam JA, Meijers JCM, Sixma JJ, Bouma BN. Inactivation of human factor VIII by activated protein C. Cofactor activity of protein S and protective effect of von Willebrand factor. J Clin Invest 1988; 82: 1236-43.
18. Simmelink MJA, Fernandez JA, Derksen RHWM, Griffin JH, De Groot PhG. Low levels of activated protein C in patients with systemic lupus erythematosus do not relate to lupus anticoagulants but to low levels of factor II. Br J Haematol 2002; 117: 676-84.